Molecule intelOpportunity: LowerEssential

Bortezomib

25 brands · 18 companies · product forms

ATC: L01XG01

Opportunity snapshot

Launch attractiveness
25
Market saturation
47
Price room
17
Regulatory risk
0
25
brands
18
companies
Rs 46,932.6
median price
24
price points
1.68x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 8%

Price room

Across observed sources and strengths
CheapestRs 35,447.02
MedianRs 46,932.6
Most expensiveRs 59,725.53
Spread1.68×
Sources: DRAP-official

max/min price ratio 1.68x across 24 trusted points (Rs 35447.02-59725.53). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 7 live products for Bortezomib — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(17) + 20% low-competition(53) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

18 canonical companies and 25 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 1.68x across 24 trusted points (Rs 35447.02-59725.53). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.